BioWorld

New inhibitors of the WRN helicase show preclinical promise for MSI-high colorectal cancers

Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Business Insider

Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy ...

While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
ascopubs.org

Efficacy and safety of immune checkpoint inhibitors in patients with unresectable metastatic colon cancer with microsatellite instability high or mismatch repair deficiency: A ...

The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine–tipiracil. MSI-H : Microsatellite instability High. dMMR : Mismatch repair deficient. RCT : Randomised ...
ascopubs.org

Consistency and Heterogeneity of Microsatellite Instability (MSI) Status in Paired Biopsy and Surgical Specimens of Colorectal Cancer: A Necessity for MSI Reassessment After ...

Intrapatient Variation in Response to Systemic Therapy in Advanced Hepatocellular Carcinoma The MSI-NGS panel showed 97% accuracy, with 112 patients exhibiting consistent MSI status between samples.